- Report
- May 2024
- 131 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Report
- May 2024
- 128 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Report
- May 2024
- 137 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Report
- December 2024
Global, Europe, United States, ... Global, Europe, United States, Japan
From €17735EUR$18,500USD£14,819GBP
- Report
- February 2025
Global, Europe, United States, ... Global, Europe, United States, Japan
From €3595EUR$3,750USD£3,004GBP
- Report
- December 2024
Mexico, Canada, North America Mexico, Canada, North America
From €9107EUR$9,500USD£7,610GBP
- Report
- December 2024
United States
From €2397EUR$2,500USD£2,003GBP
- Report
- February 2025
Middle East
From €4314EUR$4,500USD£3,605GBP
- Report
- February 2025
Canada, Mexico, North America Canada, Mexico, North America
From €2349EUR$2,450USD£1,962GBP
- Report
- February 2025
Europe, United Kingdom, ... Europe, United Kingdom, Spain, Italy, Germany, France
From €2732EUR$2,850USD£2,283GBP
- Report
- February 2025
United States
From €1390EUR$1,450USD£1,161GBP
- Report
- May 2023
- 118 Pages
Global
From €4314EUR$4,500USD£3,605GBP
- Report
- August 2022
- 138 Pages
Global
From €4314EUR$4,500USD£3,605GBP
- Report
- October 2021
- 110 Pages
United States
From €3595EUR$3,750USD£3,004GBP
- Report
- September 2022
- 225 Pages
Global
From €7190EUR$7,500USD£6,008GBP
- Drug Pipelines
- October 2021
- 50 Pages
United States
From €2157EUR$2,250USD£1,802GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1198EUR$1,250USD£1,001GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1198EUR$1,250USD£1,001GBP
- Report
- April 2023
- 140 Pages
Global
From €4744EUR$4,949USD£3,964GBP
- Report
- April 2023
- 111 Pages
Global
From €4554EUR$4,750USD£3,805GBP

The Von Willebrand Factor (VWF) is a glycoprotein found in the blood that plays an important role in hemostasis. It is a key component of the coagulation cascade, and is essential for the formation of a stable platelet plug during the clotting process. VWF is also involved in the adhesion of platelets to the site of injury, and is important for the maintenance of normal platelet function.
VWF is used in the treatment of several hematological disorders, including von Willebrand disease, thrombocytopenia, and hemophilia. VWF is available in both recombinant and plasma-derived forms, and is used in the form of concentrates, injections, and topical creams.
The VWF market is a rapidly growing segment of the hematological drugs market, driven by the increasing prevalence of hematological disorders and the growing demand for effective treatments. The market is expected to continue to grow in the coming years, driven by the development of new treatments and the increasing availability of VWF products.
Some of the major companies in the VWF market include CSL Behring, Grifols, Octapharma, Kedrion, and Shire. Show Less Read more